Marshall Wace, LLP Vaxart, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Vaxart, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,953,037 shares of VXRT stock, worth $800,745. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,953,037
Previous 1,763,882
10.72%
Holding current value
$800,745
Previous $793,000
11.35%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VXRT
# of Institutions
28Shares Held
4.41MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY1.77MShares$727,4810.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL188KShares$77,2370.0% of portfolio
-
Xtx Topco LTD London, X094.3KShares$38,6450.0% of portfolio
-
Hbk Sorce Advisory LLC Erie, PA75.1KShares$30,7980.0% of portfolio
-
Beacon Capital Management, LLC60.3KShares$24,7280.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $51.9M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...